Citations

Clear

1056 citation(s) found for "Sharma, A K".

Serologic Discrimination of Histologic Classes in Lupus Nephritis
Fatfat, Adnan , Batish, Ishaan, Sharma, Abhinav , Arevalo Salazar, Dory , Albadri, Sam , Majithia, Vikas , Aslam, Nabeel , Bobart, Shane A

Mayo Clinic

Kidney360 | November 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.34067/kid.0000001453 | PMID 43023780 Get It

Background: Anti-dsDNA positivity and hypocomplementemia are markers of active lupus nephritis (LN), but their ability to discriminate between histologic phenotypes remains underexplored, particularly for mixed proliferative/membranous LN (mixed LN). We compared baseline serologic markers across proliferative LN, membranous LN, and mixed LN, and evaluated their discriminative performance for histologic class. Methods: We conducted a retrospective cross-sectional study of 132 patients with biopsy-proven LN, categorized according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification into proliferative LN (class III/IV), membranous LN (class V), and mixed LN (class III/IV+V). Baseline anti-dsDNA and complements C3 and C4 were compared across groups. Receiver operating characteristic (ROC) analysis assessed the ability of individual and combined markers to discriminate between histologic classes. Kidney outcomes at 12 months were explored in a secondary cohort (n=88). Results: Of 132 patients, 57 had proliferative LN, 32 had membranous LN, and 43 had mixed LN. Anti-dsDNA was significantly higher, and C3 and C4 significantly lower, in proliferative and mixed LN compared to membranous LN ( P <0.05 for all), while proliferative and mixed LN did not differ significantly. On ROC analysis, individual markers achieved AUCs of 0.68-0.71 for distinguishing proliferative or mixed LN from membranous LN, with combined models yielding AUCs of 0.73. However, discrimination between proliferative and mixed LN was poor (combined AUC 0.62). At 12 months, kidney outcomes were comparable across groups. Conclusions: Mixed LN exhibits a serologic profile resembling proliferative LN, both sharing elevated anti-dsDNA and low complement levels, but distinct from membranous LN. Serology could inform suspicion for LN class but cannot replace kidney biopsy.
Characterizing bone metastases and skeletal‐related events in patients with well‐differentiated neuroendocrine neoplasms utilizing 68 Gallium ‐ DOTATATE positron emission tomography
Coston, Tucker W , Mahadevia, Himil J , Hochwald, Alex , Accurso, Joseph M , Sharma, Akash , Johnson, Geoffrey B , Ashman, Jonathan B. , Sonbol, Mohamad B , McGarrah, Patrick , Halfdanarson, Thorvardur R , Starr, Jason

Mayo Clinic

Journal of Neuroendocrinology | October 27, 2026 | Volume: 38 | Issue: 11 | Pages: No page available

10.1111/jne.70301 | PMID 42944559 Get It

Abstract Tumors of neuroendocrine origin are a heterogenous group of related neoplasms which can arise from anywhere in the body. Neuroendocrine neoplasms (NENs) are categorized by site of origin, differentiation status and grade (Ki‐67 expression and/or mitotic rate), with significant prognostic variability accordingly. Historically, the prevalence of bone metastasis is reported to be 6%–12% based on “first generation” (i.e., 111 Indium pentetreotide [Octreoscan®]) somatostatin receptor imaging (SSRI). We conducted a retrospective cohort study including patients with well‐differentiated NENs to determine the clinical and imaging characteristics of osseous metastases when evaluated with higher‐sensitivity 68 Gallium‐DOTATATE positron emission tomography (PET) scans, as well as determining fracture prevalence in selected sub‐cohorts. We also developed a risk score analysis to assess risk of fracture in this cohort. Four hundred twenty‐four patients were identified for inclusion. The median age was 61 years. Most patients were asymptomatic (64%), had sclerotic lesions (77%), Krenning 4 (71%), and had >3 sites (69%) of osseous disease. A high proportion of patients had osseous metastases at sites with high risk for fracture, including vertebra (82%), pelvis (63%), and peri‐trochanteric femur (34%). Fifty‐seven patients (13%) in the entire cohort suffered a fracture. Fracture prevalence was significantly lower in small bowel neuroendocrine tumors (NETs, 7%) and Grades 1 and 2 disease (8% and 9%, respectively), with higher prevalence in pancreatic NETs, paragangliomas/pheochromocytomas, lung carcinoid, and Grade 3 disease (≥20% for each; p ‐values <.05). Our study showed that the rate of osseous metastatic disease approximates 20% in well‐differentiated NENs. Most bone metastases are asymptomatic and the risk of fracture is variable based on the primary site of disease and tumor grade. Our novel risk score analysis for fracture was designed to assist clinician decision making as to management of bone metastasis in this patient population.
Musculoskeletal Histopathology of Klippel-Trénaunay Syndrome
Sharma, Aarti E. , Odintsov, Igor, Hung, Yin P., Folpe, Andrew L. , Hornick, Jason L., DiCarlo, Edward F., Zhang, Yaxia

Mayo Clinic

American Journal of Surgical Pathology | October 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/pas.0000000000002627 | PMID 42865064 Get It

Klippel-Trénaunay syndrome (KTS) is a rare congenital vascular-overgrowth disorder within the broader spectrum of PIK3CA -related overgrowth syndromes. Although clinical, radiologic, and orthopedic manifestations are well described, the histologic spectrum of KTS-associated pathology remains under-characterized. Clinicopathologic findings from 21 patients with clinically established KTS were reviewed, including 18 with longitudinal clinical follow-up and 3 consultation cases of rare malignant mesenchymal neoplasms. Cases were identified from institutional pathology and clinical databases, and available hematoxylin and eosin-stained sections and ancillary studies were reviewed. The cohort included 11 males and 10 females. Among the 18 clinically followed patients, 12 had limb length discrepancy or asymmetric limb overgrowth, 9 had documented deep vascular malformations, 4 had intra-articular/synovial malformations, and 10 underwent initial orthopedic evaluation or intervention before age 18. Orthopedic morbidity clustered into mechanical overgrowth-related, vascular malformation-related, and soft tissue/wound-related complications. Histologic findings included superficial and/or deep slow-flow vascular malformations, ulceration and granulation tissue, hemosiderin-laden reactive synovium, and destructive hemorrhagic arthropathy. Intra-articular disease recapitulated a hemophilic arthropathy-like pattern, with hemosiderotic synovitis, papillary synovial hyperplasia, and progressive joint destruction with loss of articular cartilage, exposed subchondral bone destruction and remodeling, all attributable to long-standing intra-articular hemorrhage. Three consultation cases showed malignant mesenchymal neoplasia, including 2 angiosarcomas. Recognition of these patterns is important for pathologists evaluating specimens from patients with known or suspected KTS, particularly when findings mimic hemophilic arthropathy, diffuse-type tenosynovial giant cell tumor, nonsyndromic vascular malformation, and/or end-stage destructive arthropathy.
Enriched Adaptive Immunity and Reduced Inflammatory Response in Plasma Cell Disorders of Self-Identified Black Patients
Pilcher, William , Khanfar, Mariam , Sharma, Neeraj , Lehman, Stacey J , Bai, Mahek, Cook, Joselle M , Abdallah, Nadine H , Bolarinwa, Abiola B , Anderson, Emilie I., Kourelis, Taxiarchis , Kumar, Shaji K , Weivoda, Megan , Gomez, Felicia

Mayo Clinic

Blood Journal | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033998 | PMID 42832394 Get It

The immune tumor microenvironment (iTME) plays a crucial role in disease biology of plasma cell (PC) dyscrasias, but remains poorly characterized in self-identified Black individuals, a population at increased risk. Mass cytometry and scRNA-seq of 128 bone marrow aspirates revealed significant changes in immune cell composition across the disease spectrum, including shifts from naïve to effector T cells with declines in B cells, MAIT, pDCs, and increases in monocytes with disease progression. Self-identified Black patients had higher relative proportions of terminally differentiated T cells and lower monocytes in newly diagnosed and treated multiple myeloma (MM). ScRNA-seq revealed genes overexpressed in self-identified Black individuals were enriched for E2F targets and G2-M checkpoints, while reduced genes were enriched for TNF-α/NF-kB, interferon and inflammatory responses pathways. These findings were supported by genetic ancestry and validated in an independent dataset of 286 patients with MM from the MMRF Immune Atlas. Self-identified race and African genetic similarity are significantly associated with remodeling the MM iTME, with potential implications for disease biology and treatment response.
Glaucoma Progression and Development Following Secondary Intraocular Lens Surgery
Wang, Kenny Y. , Hassoun, Mohamad Rani , Sharma, Kannan

Mayo Clinic

Ophthalmic Surgery, Lasers and Imaging Retina | October 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.3928/23258160-20260819-03 | PMID 42823090 Get It

Background and Objective: This study aimed to investigate glaucoma progression following secondary intraocular lens (SIOL) implantation by surgical approach. Patients and Methods: This was a single-center retrospective study of 440 eyes that received SIOL implantation, including scleral-sutured, scleral-fixated, anterior chamber, and sulcus-fixated. Glaucoma progression was defined as new diagnosis, procedure for intraocular pressure (IOP) control, or IOP elevation ≥ 24 mmHg or ≥ 5 mmHg above baseline requiring additional medications. Risk factors were assessed using multivariable analysis. Results: Mean age at surgery was 71.3 years and 29.3% of patients had prior glaucoma. Overall, 33.2% developed glaucoma progression. Prior glaucoma (hazard ratio 2.08 [95% CI 1.47–2.94], P < .001) and cystoid macular edema (1.63 [1.06–2.52], P = .026) were associated with glaucoma progression on multivariable analysis. There was no difference in glaucoma progression between scleral-sutured, scleral-fixated, anterior chamber, or sulcus-fixated implantation techniques. Conclusion: Our results suggest that surgeons should use their preferred SIOL implantation technique but closely monitor postoperative IOP.
Chemotherapy Versus Surgery for Stage IIA Nonseminomatous Germ Cell Tumor: A Comparative Cost Utility Analysis
Sharma, Vidit , Boorjian, Stephen A., Wymer, Kevin , Ratcliff, G., Penson, David F. , Leibovich, Bradley C., Costello, Brian A., Pagliaro, Lance C. , Barocas, Daniel A., Joyce, Daniel D., Boorjian, Stephen A. , Ratcliff, Grace E., Graves, John A. , Costello, Brian A. , Barocas, Daniel A.

Mayo Clinic

Journal of Urology | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ju.0000000000005317 | PMID 42758859 Get It

Exploring Women’s Perspectives on Alcohol Misuse, Treatment, and Priorities for Research: Qualitative Findings from the WomenWise Project
Tranby, Brianna , McGuinness, Audrey G., Smith, Christina M. , Vance, Tessa, Thompson, Tommi, Samocki, Matthew, Strand, Chuck, Vonada, Philip, Young, Colleen D., Boehmer, Kasey R. , Chamberlain, Alanna M. , Patten, Christi A. , Sharma, Pravesh , Vance, Tessa, Samocki, Matthew J.

Mayo Clinic

No container title available | September 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10515741/v1 Get It

Abstract Background Women remain underrepresented in alcohol use disorder (AUD) research despite sex- and gender-specific health disparities and barriers to treatment. Community-engaged approaches can identify opportunities for patient-centered comparative effectiveness research (CER) that reflect women’s lived experiences. The WomenWise project used community engaged, bi-directional, partnered learning sessions (PLS) to qualitatively explore women’s perspectives on alcohol misuse, treatment barriers, and priorities for future CER. Methods In 2025, we conducted five 90-minute PLSs via Zoom with attendees who were aged ≥ 18 years, self-identified as a woman, reported lived experience of alcohol misuse, were a family member/caregiver of a woman with AUD, and were affiliated with a WomenWise partner organization or a healthcare provider treating AUD. Moderated PLSs focused on bi-directional knowledge exchange and sharing of experiences. Audio transcripts, Zoom chat content, and one asynchronous online discussion thread were analyzed using reflexive thematic analysis. Suggested future CER topics generated during sessions were presented to the WomenWise community advisory board (CAB), which ranked priority topics by vote. Results In total, 51 attendees shared their experiences. The major themes centered on a sense of shame and stigma unique to women, with many attendees mentioning gendered norms, “mom culture,” “quiet drinking,” and caregiver role strain. Barriers to treatment included structural challenges, poor healthcare provider communication, the need for trauma-informed care, and concerns about privacy particularly in rural areas. Six future CER topics emerged, of which the CAB selected three priorities: (1) harm reduction/moderation versus abstinence-only approaches, (2) trauma-focused care versus standard AUD treatment, and (3) care access and engagement strategies. Conclusions These bidirectional, co-learning sessions identified patient-centered, community-informed priorities for future AUD research in women. The findings highlight the importance of addressing stigma, trauma, structural barriers, and provider communication when designing future women-centered treatment studies and care models.
From Housing to Hotspots: Integrating a Housing-Based Measure of Individual Socioeconomic Status with Geospatial Analysis to Target Colorectal Cancer Screening in Rural Communities
Yao, Rebecca , Beenken, Madison, Watson, Dave , Wheeler, Philip H., Finch, Mike, Kelleher, Dan , Anil, Gokhan , Anderson, Trent, Madden, Kathy A., Okuno, Scott H. , Odedina, Folakemi T., Park, Eunice , Dugani, Sagar B., Sosso, Jessica , Sabarish, Shivani , Singh, Gurpreet, Lugo-Fagundo, Nahyr, Kim, W. Ray, Walker-Mcgill, Cheryl L., Juhn, Young J. , Lynch, Brian , Wi, Chung‐Il , Madden, Kathy A., Westfall, Erin , Sharma, Pravesh , Dugani, Sagar B. , Foss, Randy , Hidaka, Brandon H. , Singh, Gurpreet, Howick V, James F , Calvin, Andrew D. , Walker-McGill, Cheryl Lynn, Rennert, Lior , Cerhan, James R. , Beenken, Madison J, Kelleher, Dan P., Westfall, Erin C, Park, Eunice Y., Sharma, Pravesh , Foss, Randy M, Sosso, Jessica L

Mayo Clinic

No container title available | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.28.26361444 | PMID 42922856 Get It

ABSTRACT Purpose This study assesses the association between colorectal cancer (CRC) screening and a validated, housing-based measure of individual-level socioeconomic status (SES, called HOUSES hereafter) within rural communities and determines whether HOUSES-integrated geospatial analysis can be used to tailor interventions. Methods We used CRC screening data from a subset of Mayo Clinic Midwest patients living in cities without ready access to routine care in the Mayo Clinic Health System in 2019 to represent rural communities. At the individual level, we assessed the association between CRC screening rates and the HOUSES index, adjusting for age, sex, race/ethnicity, comorbidity, distance from home address to clinic, and area deprivation index, using a multilevel mixed-effects logistic regression model. Additionally, we conducted geospatial analysis to examine the correlation between hotspots of 1) lower CRC screening rates and 2) lower SES of the subject population (HOUSES quartile 1). Findings Among 34,489 individuals (median age 64.0 years, 52.4% female), those with the lowest SES (HOUSES Q1) had 37% lower odds of being CRC screening adherent than those with the highest SES (HOUSES Q4) (adj. OR [95% CI]: 0.63 [0.58-0.69]). In the 14 identified HOUSES Q1 hotspots, there was a significant correlation in counts of HOUSES Q1 and low CRC screening (correlation coefficient=0.81). Conclusion Lower SES was significantly associated with lower CRC screening among rural populations. HOUSES-enabled geospatial analysis identified geographic hotspots with lower CRC screening rates for targeted interventions to address disparities in CRC screening in rural communities. HOUSES may be a useful digital tool for cancer preventive care and research.
Initial Staging 18 F-FDG PET/CT for Coronary Artery Calcium Scoring to Assess Cardiovascular Risk in Women with Breast Cancer
Fleming, Matthew R. , Tayon, Kevin G., McPherson, Alyssa, Bianco, Sidney M., Lin, Grace , Norton, Nadine , Ray, Jordan , Lin, Grace , Norton, Nadine , Tayon, Kevin G. , Schneider, Artur , Parent, Ephraim E. , Sharma, Akarsh

Mayo Clinic

No container title available | August 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.24.26361275 Get It

Abstract Background. Cardiovascular disease is a leading cause of death among women with breast cancer, and the 2026 ACC/AHA dyslipidemia guideline endorses coronary artery calcium (CAC) scoring to guide statin therapy before cardiotoxic treatment. Breast cancer patients routinely undergo staging 18 F-fluorodeoxyglucose PET/CT, whose low- dose CT visualizes the coronary arteries, thus enabling CAC quantification at no additional cost or radiation. Methods In this single-center retrospective study, consecutive women with newly diagnosed breast cancer undergoing staging 18 F-FDG PET/CT (2009–2021) had semi- automated Agatston CAC scoring performed on the low-dose CT and were stratified by CAC presence (CAC-P) versus absence (CAC-A). We assessed a composite of cardiac diagnostic testing (stress testing, coronary CT angiography, invasive angiography), clinical events, and reclassification of statin eligibility per ACC/AHA guideline thresholds in a prevention-eligible subgroup. Results Among 276 women (mean age 55.5 years; median follow-up 7.1 years), CAC was present in 68 (25%) but was clinically reported in only 5.4%. CAC-P was associated with more cardiac testing (34% vs 12%; age-adjusted hazard ratio 2.75, 95% CI 1.43–5.28) and, though underpowered, with more atherosclerotic events (7.4% vs 1.4%), but not with the all-cause composite. In the prevention-eligible subgroup (n=39), CAC scoring would have changed statin eligibility in 64%, initiating therapy in 62% of CAC-P women and supporting de-prescribing in 67% of CAC-A women. Conclusions CAC can be feasibly quantified from staging PET/CT in women with breast cancer and would frequently reclassify statin eligibility at no additional cost or radiation, yet is rarely reported.
Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Adjuvant Therapy for Resected Adenocarcinoma of the Pancreas
Jethwa, Krishan R., Newman, Neil, Selfridge, J. Eva, Anker, Christopher J., Abood, G., Akselrod, Dmitriy, Attallah, Joseph, Hallemeier, Christopher L., Jin, Zhaohui, Kim, Ed, Kennedy, Timothy, Lee, Percy, Ling, Diane C., Miller, Eric D, Sharma, Navesh, Small, William, Tchelebi, Leila, Russo, Suzanne , Jethwa, Krishan R. , Newman, Neil B. , Anker, Christopher J. , Abood, Gerard, Akselrod, Dmitriy , Hallemeier, Christopher Leigh , Hassett, Leslie C. , Lee, Percy, Small, William , Tchelebi, Leila T.

Mayo Clinic

American Journal of Clinical Oncology | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/coc.0000000000001347 | PMID 42622289 Get It

Objectives: Rates of locoregional recurrence and distant metastases are high following curative-intent resection for patients with localized pancreatic adenocarcinoma. Adjuvant therapies have been investigated with the intent to reduce the risk of recurrence and improve OS. The objective of this study is to update and summarize the current evidence for adjuvant therapy following surgical resection for nonmetastatic PDAC with a focus on high-level evidence and randomized controlled trials is provided. Methods: This multispecialty-led committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and surgical oncology. Using the population, intervention, comparator, outcome, timing and study design framework, evidence regarding treatment outcomes was assessed using Cochrane and PRISMA methodology. Eligible studies included prospective and retrospective (n≥25) studies published between January 1, 2013 and February 13, 2026, from Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Database of Systematic Review, and Scopus databases. Study type and quality were assessed. Well-established RAND/UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options. Results: Of the 74 references used as evidence, 74 are categorized as therapeutic references. Study type and quality for the references were assessed, and included 31 well-designed studies (phase II randomized and phase III), 14 moderately well-designed studies that account for most common biases (matched cohort and phase II studies), 28 studies with design limitations (retrospective reviews), and 1 reference meta-analysis. Conclusions: This systematic review and guidelines provide up-to-date recommendations focusing on recent advancements for adjuvant treatment of resected PDAC using modern systemic therapy regimens and selective use of radiotherapy using modern techniques.